219 related articles for article (PubMed ID: 30416119)
21. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.
Szabo ST; Thorpy MJ; Mayer G; Peever JH; Kilduff TS
Sleep Med Rev; 2019 Feb; 43():23-36. PubMed ID: 30503715
[TBL] [Abstract][Full Text] [Related]
22. Circuit mechanisms of sleepiness and cataplexy in narcolepsy.
Pintwala S; Peever J
Curr Opin Neurobiol; 2017 Jun; 44():50-58. PubMed ID: 28343142
[TBL] [Abstract][Full Text] [Related]
23. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
[TBL] [Abstract][Full Text] [Related]
24. Challenges in the development of therapeutics for narcolepsy.
Black SW; Yamanaka A; Kilduff TS
Prog Neurobiol; 2017 May; 152():89-113. PubMed ID: 26721620
[TBL] [Abstract][Full Text] [Related]
25. Sodium oxybate for excessive daytime sleepiness in narcolepsy-cataplexy.
Arnulf I; Mignot E
Sleep; 2004 Nov; 27(7):1242-3. PubMed ID: 15586777
[No Abstract] [Full Text] [Related]
26. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
27. Emerging treatments for narcolepsy and its related disorders.
Nishino S; Okuro M
Expert Opin Emerg Drugs; 2010 Mar; 15(1):139-58. PubMed ID: 20166851
[TBL] [Abstract][Full Text] [Related]
28. Brain Circuits Underlying Narcolepsy.
Pintwala SK; Peever J
Neuroscientist; 2023 Dec; 29(6):751-766. PubMed ID: 34704497
[TBL] [Abstract][Full Text] [Related]
29. Narcolepsy: pathophysiology and pharmacology.
Nishino S
J Clin Psychiatry; 2007; 68 Suppl 13():9-15. PubMed ID: 18078360
[TBL] [Abstract][Full Text] [Related]
30. Pitolisant for treating patients with narcolepsy.
Li S; Yang J
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
[No Abstract] [Full Text] [Related]
31. Narcolepsy in the older adult: epidemiology, diagnosis and management.
Chakravorty SS; Rye DB
Drugs Aging; 2003; 20(5):361-76. PubMed ID: 12696996
[TBL] [Abstract][Full Text] [Related]
32. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.
Mahoney CE; Mochizuki T; Scammell TE
Sleep; 2020 Jun; 43(6):. PubMed ID: 31830270
[TBL] [Abstract][Full Text] [Related]
33. Novel therapies for narcolepsy.
Brooks S; Black J
Expert Opin Investig Drugs; 2002 Dec; 11(12):1821-7. PubMed ID: 12457441
[TBL] [Abstract][Full Text] [Related]
34. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
Black J; Swick T; Bogan R; Lai C; Carter LP
Sleep Med; 2016 Aug; 24():57-62. PubMed ID: 27810187
[TBL] [Abstract][Full Text] [Related]
35. Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice.
Katzav A; Arango MT; Kivity S; Tanaka S; Givaty G; Agmon-Levin N; Honda M; Anaya JM; Chapman J; Shoenfeld Y
J Autoimmun; 2013 Sep; 45():24-30. PubMed ID: 23834844
[TBL] [Abstract][Full Text] [Related]
36. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions.
Zeitzer JM; Nishino S; Mignot E
Trends Pharmacol Sci; 2006 Jul; 27(7):368-74. PubMed ID: 16766052
[TBL] [Abstract][Full Text] [Related]
37. [Advances in the diagnosis and treatment of narcolepsy-cataplexy syndrome].
de Vicente Alvarez-Manzaneda EE
Rev Neurol; 2008 May 1-15; 46(9):550-6. PubMed ID: 18446698
[TBL] [Abstract][Full Text] [Related]
38. [Narcolepsy with and without cataplexy: an uncommon disabling and unrecognized disease].
Merino-Andréu M; Martínez-Bermejo A
An Pediatr (Barc); 2009 Dec; 71(6):524-34. PubMed ID: 19892609
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of action of narcolepsy medications.
Gowda CR; Lundt LP
CNS Spectr; 2014 Dec; 19 Suppl 1():25-33; quiz 25-7, 34. PubMed ID: 25403789
[TBL] [Abstract][Full Text] [Related]
40. Nonpeptide Orexin-2 Receptor Agonist Attenuates Morphine-induced Sedative Effects in Rats.
Toyama S; Shimoyama N; Tagaito Y; Nagase H; Saitoh T; Yanagisawa M; Shimoyama M
Anesthesiology; 2018 May; 128(5):992-1003. PubMed ID: 29521652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
